Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas

Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells

(2020) Anna Śledzińska et al.   IMMUNITY

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

(2020) George W. Wright et al.   CANCER CELL

Immunogenomic Landscape of Hematological Malignancies

(2020) Olli Dufva et al.   CANCER CELL

The GTEx Consortium atlas of genetic regulatory effects across human tissues

(2020)   SCIENCE

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

(2019) Daisuke Ennishi et al.   Cancer Discovery

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

(2019) Marian L. Burr et al.   CANCER CELL

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

(2019) Michal Harel et al.   CELL

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

(2019) David A. Schaer et al.   CLINICAL CANCER RESEARCH

Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers

(2019) Liye Zhou et al.   CLINICAL CANCER RESEARCH

Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity

(2019) Michael D. Nissen et al.   CYTOMETRY PART A

MHC-II neoantigens shape tumour immunity and response to immunotherapy

(2019) Elise Alspach et al.   NATURE

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

(2018) Sophia S. Wang et al.   CANCER RESEARCH

Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

(2018) Katherine A. Hoadley et al.   CELL

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

A multiprotein supercomplex controlling oncogenic signalling in lymphoma

(2018) James D. Phelan et al.   NATURE

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma

(2018) Li Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging EZH2 Inhibitors and Their Application in Lymphoma

(2018) Jennifer K. Lue et al.   Current Hematologic Malignancy Reports

STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

(2018) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Noncoding regions are the main source of targetable tumor-specific antigens

(2018) Céline M. Laumont et al.   Science Translational Medicine

Mapping the MHC Class I–Spliced Immunopeptidome of Cancer Cells

(2018) Juliane Liepe et al.   Cancer Immunology Research

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

(2017) Marcel Nijland et al.   OncoImmunology

MultiQC: summarize analysis results for multiple tools and samples in a single report

(2016) Philip Ewels et al.   BIOINFORMATICS

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

(2016) John G Doench et al.   NATURE BIOTECHNOLOGY

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas

(2016) Yanwen Jiang et al.   Cancer Discovery

Translation elongation factor eEF1A1 is a novel partner of a multifunctional protein Sgt1

(2015) Oleksandra Novosylna et al.   BIOCHIMIE

Epigenetic regulation of differentialHLA-Aallelic expression levels

(2015) Veron Ramsuran et al.   HUMAN MOLECULAR GENETICS

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation

(2015) Michael R. Green et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module

(2015) Kristina Ludigs et al.   PLoS Genetics

TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst

(2015) Clemens Hermann et al.   eLife

Mutational analysis of primary central nervous system lymphoma

(2015) Aurélie Bruno et al.   Oncotarget

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms

(2014) Jay A. Read et al.   Clinical Lymphoma Myeloma & Leukemia

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

The IPD and IMGT/HLA database: allele variant databases

(2014) James Robinson et al.   NUCLEIC ACIDS RESEARCH

The central role of EED in the orchestration of polycomb group complexes

(2014) Qi Cao et al.   Nature Communications

Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis

(2013) Marieta Caganova et al.   JOURNAL OF CLINICAL INVESTIGATION

Degradation of Newly Synthesized Polypeptides by Ribosome-Associated RACK1/c-Jun N-Terminal Kinase/Eukaryotic Elongation Factor 1A2 Complex

(2013) V. Gandin et al.   MOLECULAR AND CELLULAR BIOLOGY

Tapasin-related protein TAPBPR is an additional component of the MHC class I presentation pathway

(2013) Louise H. Boyle et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Targeting the JMJD2 Histone Demethylases to Epigenetically Control Herpesvirus Infection and Reactivation from Latency

(2013) Y. Liang et al.   Science Translational Medicine

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

(2013) W Kraan et al.   Blood Cancer Journal

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression

(2012) T. B. Meissner et al.   JOURNAL OF IMMUNOLOGY

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Next-generation sequencing for HLA typing of class I loci

(2011) Rachel L Erlich et al.   BMC GENOMICS

Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

(2011) Madhavi Challa-Malladi et al.   CANCER CELL

FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas

(2011) Shanshan Duan et al.   NATURE

DRiPs solidify: progress in understanding endogenous MHC class I antigen processing

(2011) Jonathan W. Yewdell   TRENDS IN IMMUNOLOGY

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

(2010) D. B. Yap et al.   BLOOD

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

(2010) Jun Cui et al.   CELL

Structural Basis for Assembly of Hsp90-Sgt1-CHORD Protein Complexes: Implications for Chaperoning of NLR Innate Immunity Receptors

(2010) Minghao Zhang et al.   MOLECULAR CELL

Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- B pathways in subtypes of diffuse large B-cell lymphoma

(2007) L. T. Lam et al.   BLOOD